Neuraxis, INC
No SEC Form 4 filings for $NRXS in the last 30 days.
See all $NRXS insider activity →NeurAxis (NRXS) reported Q2 2026 revenue of $1.928 million, up 116% year over year, driven by increased payer and reimbursement coverage, with IB-Stim ASP rising to $992 per device (+28%). Gross margin was 85.9%. Operating loss was $2.1 million and net loss $2.1 million. Cash on hand was $8.3 million as of June 30, 2026.
NeurAxis (NRXS) reported Q2 2026 revenue of $1.9M, up 116% from $0.9M in Q2 2025, citing expanded payer coverage after Category I CPT code assignment for PENFS. Gross margin rose 230 bps. Operating cash use improved to $1.0M, with cash of $8.3M at June 30, 2026. The company also cited VA contract access and FDA clearance for IB-Stim.
NeurAxis (NYSE American: NRXS) reported Q2 2026 revenue of $1.9M, up 116% year over year, citing PENFS Category I CPT code coverage effective Jan. 1, 2026. Gross margin rose to 85.9%. Cash was $8.3M at June 30, 2026. The company also cited VA FSS contract and FDA clearance for functional dyspepsia abdominal pain.
Over the past 7 days, alphai's AI scored 3 news stories mentioning NRXS (Neuraxis, INC). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent NRXS coverage spans financial news, earnings and corporate actions.
The call provides fresh operating metrics (ASP, gross margin, prior auth rate, ordering accounts) plus cash/burn and an ATM status update, shaping near-term valuation and risk.
The quarter’s growth is tied to reimbursement and commercialization catalysts (CPT code, VA contract, FDA clearance), which can support near-term demand expectations.
The quarter’s growth is explicitly tied to payer coverage expansion and higher full-reimbursement device sales, plus new FDA clearance and a VA FSS contract.
This is a corporate-governance/equity-plan update tied to a shareholder vote; it can affect dilution expectations and incentive structure but provides no deal/earnings numbers.
Neuraxis Inc expects approximately $1.6 million in net sales for Q1 2026, indicating potential growth and positive market perception.
alphai scores every news story that mentions NRXS with an AI model for sentiment and relevance, and aggregates insider trades from Neuraxis, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
NeurAxis (NRXS) reported Q2 2026 revenue of $1.928 million, up 116% year over year, driven by increased payer and reimbursement coverage, with IB-Stim ASP rising to $992 per device (+28%). Gross margin was 85.9%. Operating loss was $2.1 million and net loss $2.1 million. Cash on hand was $8.3 million as of June 30, 2026.
6 min readNeurAxis (NRXS) reported Q2 2026 revenue of $1.9M, up 116% from $0.9M in Q2 2025, citing expanded payer coverage after Category I CPT code assignment for PENFS. Gross margin rose 230 bps. Operating cash use improved to $1.0M, with cash of $8.3M at June 30, 2026. The company also cited VA contract access and FDA clearance for IB-Stim.
4 min readNeurAxis (NYSE American: NRXS) reported Q2 2026 revenue of $1.9M, up 116% year over year, citing PENFS Category I CPT code coverage effective Jan. 1, 2026. Gross margin rose to 85.9%. Cash was $8.3M at June 30, 2026. The company also cited VA FSS contract and FDA clearance for functional dyspepsia abdominal pain.
4 min readNeuraxis, INC (NRXS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan (As Amended As of June 11, 2026) Table of Contents Page ARTICLE I PURPOSE 1 ARTICLE II DEFINITIONS 1 ARTICLE III EFFECTIVE DATE OF PLAN 6 ARTICLE IV ADMINISTRATION 6 Section 4.1 Ad
2 min readNeuraxis Inc has announced its net sales expectations for the three months ending March 31, 2026. The company anticipates achieving approximately $1.6 million in net sales during this period. This news was reported by Reuters.
2 min readNeurAxis posts its fifth straight quarter of double-digit expansion, but rising costs and margin pressure weigh on third-quarter 2025 results.
3 min readCARMEL, Ind., Nov. 12, 2025 ( GLOBE NEWSWIRE ) -- NeurAxis, Inc. ( "NeurAxis" or the "Company" ) ( NYSE:NRXS ) , a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced new medical policy coverage for ...
3 min readAchieves significant expansion of NeurAxis' total addressable market Clearance now includes patients aged "8 years and older" Expanded age indication will utilize the upcoming January 1st, 2026, Category I CPT code to report PENFS procedures
3 min readCARMEL, Ind., June 17, 2025 ( GLOBE NEWSWIRE ) -- NeurAxis, Inc. ( "NeurAxis," or the "Company" ) ( NYSE American: NRXS ) , a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy ...
2 min readCARMEL, Ind., May 22, 2025 ( GLOBE NEWSWIRE ) -- NeurAxis, Inc. ( "NeurAxis," or the "Company" ) NRXS, a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the closing of its previously ...
2 min read
